Laser Diffraction Software Supports Analytical QbD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Laser Diffraction Software Supports Analytical QbD


Pharmaceutical Technology
Volume 38, Issue 5, pp. 2

A software upgrade for the Mastersizer 3000 laser diffraction particle size analyzer from Malvern Instruments decreases the analytical workload associated with developing and validating particle sizing methods. New operational features, such as an Optical Property Optimizer (OPO ), simplify the process of method development. The new OPO tool enables the identification of appropriate refractive index and absorption values for the analysis of any given sample. It also allows analysts to research the impact of optical properties on reported particle size, in real time, using an intuitive point-and-click tool. According to the company, this helps exploration of the operating space in which robust measurements are assured, to define the method operable design region for a particle size analysis method.

Malvern Instruments

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here